Microdose and Journey Clinical Announce Partnership To Expand Accessibility Through 'The Science of Psychedelics' Course
Toronto, Ontario--(Newsfile Corp. - September 14, 2022) - Microdose Psychedelic Insights, the leading guide to the business of psychedelics, is thrilled to announce its partnership with Journey Clinical to better equip medical professionals with knowledge and access to evidence-based psychedelic-assisted psychotherapies through The Science of Psychedelics program.
Psychedelic medicine has ushered a new paradigm in the field of mental health care. The psychedelic therapy approach to healthcare has strict guidelines, safety protocols and training requirements. The Microdose and Journey Clinical partnership aims to create a collaborative space to advocate for the next generation of psychedelic medicine while bringing awareness, fostering community, educating, and sparking long-lasting connections.
"We are excited about this partnership with Journey Clinical. As leaders in ketamine-assisted therapy, they are able to provide practical resources for students of The Science of Psychedelics course. We are confident that The Science of Psychedelics students and Journey Clinical members alike will benefit from this new opportunity," said Connor Haslam, CEO of Microdose Psychedelic Insights.
Journey Clinical is expanding access to Psychedelic-Assisted Psychotherapy, starting with Ketamine-Assisted Psychotherapy (KAP). The company currently supports licensed mental health professionals in New York, California, New Jersey, Massachusetts and Colorado.
A growing number of licensed mental health professionals around the country want to deliver psychedelic therapies in their practice but don't know where to start. In line with our vision to advance dynamic conversations and provide leading insights pertaining to the psychedelic industry, Microdose is delighted to announce our partnership with Journey Clinical. Together, we offer members of Journey Clinical and certificate holders of The Science of Psychedelics the opportunity to turn knowledge into practice. Graduates receive a 10% off their monthly membership to Journey Clinical's platform for the first year.
The Science of Psychedelics course is CE and CME accredited and is the definitive guide to the application of entheogenic medicines, offering a solid foundation and guide for psychedelic-assisted therapy.
If you are a licensed mental health professional, you can apply to join Journey Clinical membership. All Microdose community members will enjoy 10% off of their monthly membership for their first year. Click here to learn more and apply to join.
About Microdose Psychedelic Insights
Microdose Psychedelic Insights aims to unlock the potential of psychedelic medicine through Industry events, market intelligence, original, evidence-based content, strategy, and community. We enable and empower society at large to make better, more mindful decisions about psychedelics and their intersection with healthcare, medicine, and personal growth. We work with the industry's most influential stakeholders, some of the world's best-known brands, and an unrivalled network of scientists, researchers, analysts, innovators, investors, and advisors.
PR contact: email@example.com
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/136975